Phenotypes Associated with This Genotype

Genotype
MGI:3759301

• Allelic Composition: Dlgap3^tm1Gfng/Dlgap3^tm1Gfng
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

enhanced behavioral response to xenobiotic ( J:125181 )

• grooming behavior and anxiety-related behaviors are reduced following treatment with fluoxetine for 6 days whereas grooming behavior in similarly treated wild-type mice is unchanged

• treatment with fluoxetine for 6 days reduced the number of sleeping bouts and increased the sleeping time per bout

• however, a single treatment of fluoxetine has no effect on grooming behavior

increased anxiety-related response ( J:125181 )

• in a dark-light test, mice take more time to cross from the dark to the lit chamber and spent less time in the lit chamber compared to wild-type mice

• however, activity levels overall are normal and treatment with fluoxetine for 6 days reduces anxiety-related behaviors in a dark-light test without affecting total activity levels

• in an elevated zero maze test, mice take longer to cross into the open areas and spent less time exploring than do wild-type mice

increased thigmotaxis ( J:125181 )

• in an open field test mice spend more time long walls and spend less time exploring than do wild-type mice

• however, activities along the walls and in corners is normal

increased grooming behavior ( J:125181 )

• mice exhibit increased grooming bouts and spend more time self-grooming prior to lesion formation than do wild-type mice

• however, grooming behavior is reduced following treatment with fluoxetine for 6 days whereas grooming behavior in similarly treated wild-type mice is unchanged

abnormal sleep pattern ( J:125181 )

• mice sleep less during normal sleeping periods and sleep more during active times compared to wild-type mice

• mice have increased sleeping bouts but the time slept per bout was reduced relative to in wild-type mice

• however, treatment with fluoxetine for 6 days reduces the number of sleeping bouts and increases the sleeping time per bout

nervous system

abnormal striatum morphology ( J:125181 )

• the thickness of the dense layer, but not the light layer, in postsynaptic densities of cortico-striatal synapses is reduced compared to in wild-type mice

abnormal excitatory postsynaptic potential ( J:125181 )

• field excitatory postsynaptic potential (fEPSP) in the presence of picrotoxin is decreased compared to in wild-type mice

• NMDAR-dependent fEPSP amplitudes are increased relative to in wild-type mice

• however, axon excitability and presynaptic function are normal as is CA3-CA1 hippocampal basal synaptic transmission

enhanced NMDA-mediated synaptic currents ( J:125181 )

• NMDAR-dependent fEPSP amplitudes are increased relative to in wild-type mice

• however, CA3-CA1 hippocampal basal synaptic transmission is normal

integument

skin lesions ( J:125181 )

• by 4 to 6 months, all mice develop lesions on their heads, neck and snout regions

• lesions begin as hairless skin under eyes, or swelling of the snout and progress to relatively symmetrical bilateral lesions encompassing large parts of the head and neck

• skin with lesions contains increased lymphocytic/granulocytic infiltrate

• however, pre-lesion mouse skin is normal